Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial comphcations

Journal of Virology

Volumn 84, Issue 8, 2010, Pages 4105-4108

  Huber, Victor C ^a   Peltola, Ville ^b   Iverson, Amy R ^a   McCullers, Jonathan A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FORMALDEHYDE; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS HEMAGGLUTININ ANTIBODY; VIRUS SIALIDASE; VIRUS SIALIDASE ANTIBODY; HEMAGGLUTININ FUSOGENIC PEPTIDE, INFLUENZA VIRUS; NA PROTEIN, INFLUENZA A VIRUS; SIALIDASE; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SECONDARY INFECTION; VIRUS INACTIVATION; ANIMAL; BACTERIAL PNEUMONIA; BAGG ALBINO MOUSE; BLOOD; FEMALE; HUMAN; IMMUNOLOGY; ORTHOMYXOVIRUS INFECTION;

BACTERIA (MICROORGANISMS); MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA, BACTERIAL; VIRAL PROTEINS;

EID: 77950507120     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02621-09     Document Type: Article

References (33)

1. Ailing, D. W., W. C. Blackwelder, and C. H. Stuart-Harris. 1981. A study of excess mortality during influenza epidemics in the United States, 1968-1976. Am. J. Epidemiol. 113: 30-43.
2. Aminoff, D. 1959. The determination of free sialic acid in the presence of the bound compound. Virology 7: 355-357.
3. Aminoff, D. 1961. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem. J. 81: 384-392.
4. Clements, D. A., L. Langdon, C. Bland, and E. Walter. 1995. Influenza A vaccine decreases the incidence of otitis media in 6-to 30-month-old children in day care. Arch. Pediatr. Adolesc. Med. 149: 1113-1117.
5. Collins, S. D., and J. Lehmann. 1951. Trends and epidemics of influenza and pneumonia: 1918-1951. Public Health Rep. 66: 1487-1516.
6. Drape, R. J., M. D. Macklin, L. J. Barr, S. Jones, J. R. Haynes, and H. J. Dean. 2006. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24: 4475-4481.
7. Eichelberger, M., H. Golding, M. Hess, J. Weir, K. Subbarao, C. J. Luke, M. Friede, and D. Wood. 2008. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26: 4299-4303.
8. Fiore, A. E., D. K. Shay, K. Broder, J. K. Iskander, T. M. Uyeki, G. Mootrey, J. S. Bresee, and N. J. Cox. 2009. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm. Rep. 58: 1-52.
9. Hassantoufighi, A., H. Zhang, M. Sandbulte, J. Gao, J. Manischewitz, L. King, H. Golding, T. M. Straight, and M. C. Eichelberger. 2010. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 28: 790-797.
10. Hoffmann, E., G. Neumann, Y. Kawaoka, G. Hobom, and R. G. Webster. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97: 6108-6113.
11. Hoffmann, E., and R. G. Webster. 2000. Unidirectional RNA polymerase I-polymerase II transcription system for the generation of influenza A virus from eight plasmids. J. Gen. Virol. 81: 2843-2847.
12. Huber, V. C., L. H. Kleimeyer, and J. A. McCullers. 2008. Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine 26: 5381-5388.
13. Huber, V. C., and J. A. McCullers. 2008. FluBlok, a recombinant influenza vaccine. Curr. Opin. Mol. Ther. 10: 75-85.
14. Huber, V. C., R. M. McKeon, M. N. Brackin, L. A. Miller, R. Keating, S. A. Brown, N. Makarova, D. R. Perez, G. H. Macdonald, and J. A. McCullers. 2006. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. 13: 981-990.
15. Huber, V. C., P. G. Thomas, and J. A. McCullers. 2009. A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine 27: 1192-1200.
16. Kilbourne, E. D., W. N. Christenson, and M. Sande. 1968. Antibody response in man to influenza virus neuraminidase following influenza. J. Virol. 2: 761-762.
17. Kilbourne, E. D., W. G. Laver, J. L. Schulman, and R. G. Webster. 1968. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J. Virol. 2: 281-288.
18. Kilbourne, E. D., B. A. Pokorny, B. Johansson, I. Brett, Y. Milev, and J. T. Matthews. 2004. Protection of mice with recombinant influenza virus neuraminidase. J. Infect. Dis. 189: 459-461.
19. Loosli, C. G. 1973. Influenza and the interaction of viruses and bacteria in respiratory infections. Medicine (Baltimore) 52: 369-384.
20. McCullers, J. A., and K. C. Bartmess. 2003. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J. Infect. Dis. 187: 1000-1009.
21. McCullers, J. A., and J. E. Rehg. 2002. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J. Infect. Dis. 186: 341-350.
22. Morens, D. M., and A. S. Fauci. 2007. The 1918 influenza pandemic: insights for the 21st century. J. Infect. Dis. 195: 1018-1028.
23. Morens, D. M., J. K. Taubenberger, and A. S. Fauci. 2008. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198: 962-970.
24. Ozgur, S. K., U. Beyazova, Y. K. Kemaloglu, I. Maral, F. Sahin, A. D. Camurdan, Y. Kizil, E. Dinc, and H. Tuzun. 2006. Effectiveness of inactivated influenza vaccine for prevention of otitis media in children. Pediatr. Infect. Dis. J. 25: 401-404.
25. Peltola, V. T., and J. A. McCullers. 2004. Respiratoryviruses predisposing to bacterial infections: role of neuraminidase. Pediatr. Infect. Dis. J. 23: S87-S97.
26. Peltola, V. T., K. G. Murti, and J. A. McCullers. 2005. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J. Infect. Dis. 192: 249-257.
27. Powers, D. C., E. D. Kilbourne, and B. E. Johansson. 1996. Neuraminidasespecific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin. Diagn. Lab. Immunol. 3: 511-516.
28. Reichert, T. A., L. Simonsen, A. Sharma, S. A. Pardo, D. S. Fedson, and M. A. Miller. 2004. Influenza and the winter increase in mortality in the United States, 1959-1999. Am. J. Epidemiol. 160: 492-502.
29. Sandbulte, M. R., G. S. Jimenez, A. C. Boon, L. R. Smith, J. J. Treanor, and R. J. Webby. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4: e59.
30. Simonsen, L., K. Fukuda, L. B. Schonberger, and N. J. Cox. 2000. The impact of influenza epidemics on hospitalizations. J. Infect. Dis. 181: 831-837.
31. Smith, D. J., A. S. Lapedes, J. C. De Jong, T. M. Bestebroer, G. F. Rimmelzwaan, A. D. Osterhaus, and R. A. Fouchier. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305: 371-376.
32. Sun, K., and D. W. Metzger. 2008. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat. Med. 14: 558-564.
33. Warren, L. 1959. The thiobarbituric acid assay of sialic acids. J. Biol. Chem. 234: 1971-1975.